Literature DB >> 19374880

Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells.

Brian D Lamon1, Barbara D Summers, Antonio M Gotto, David P Hajjar.   

Abstract

Statins have been demonstrated to elicit a broad range of cellular events resulting in an attenuation of the inflammatory response and enhanced protection to the components of the vessel wall. The present study was designed to examine the effect of pitavastatin on pathways associated with the proinflammatory gene, early growth response (Egr)-1, in human vascular smooth muscle cells. Pretreatment with pitavastatin resulted in a dose-dependent reduction in Egr-1 protein and suppressed Egr-1 mRNA expression in response to phorbol 12-myristate 13-acetate (PMA). A reduction in Egr-1 expression reduced the activation of NGFI-A binding protein (NAB)-2, an Egr-1-dependent gene. Furthermore, these events appeared to be dependent on the ability of pitavastatin to attenuate signaling cascades associated with extracellular regulated kinase (ERK) 1/2, but not p38 and c-Jun N-terminal kinase (JNK).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374880      PMCID: PMC2671580          DOI: 10.1016/j.ejphar.2008.12.047

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  33 in total

1.  Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress.

Authors:  S F Yan; T Fujita; J Lu; K Okada; Y Shan Zou; N Mackman; D J Pinsky; D M Stern
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

2.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Authors:  F S Santiago; H C Lowe; M M Kavurma; C N Chesterman; A Baker; D G Atkins; L M Khachigian
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

3.  Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2.

Authors:  Tadashi Yamakawa; Shun-ichi Tanaka; Junzo Kamei; Kazuaki Kadonosono; Kenji Okuda
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

4.  A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.

Authors:  Yasushi Saito; Nobuhiro Yamada; Tamio Teramoto; Hiroshige Itakura; Yoshiya Hata; Noriaki Nakaya; Hiroshi Mabuchi; Motoo Tushima; Jun Sasaki; Nobuya Ogawa; Yuichiro Goto
Journal:  Atherosclerosis       Date:  2002-06       Impact factor: 5.162

5.  High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis.

Authors:  T A McCaffrey; C Fu; B Du; S Eksinar; K C Kent; H Bush; K Kreiger; T Rosengart; M I Cybulsky; E S Silverman; T Collins
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

6.  Matrix-dependent gene expression of egr-1 and PDGF A regulate angiotensin II-induced proliferation in human vascular smooth muscle cells.

Authors:  S Ling; A Dai; Y H Ma; E Wilson; K Chatterjee; H E Ives; K Sudhir
Journal:  Hypertension       Date:  1999-11       Impact factor: 10.190

7.  Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-beta type II receptor.

Authors:  B Du; C Fu; K C Kent; H Bush; A H Schulick; K Kreiger; T Collins; T A McCaffrey
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

8.  Hemin upregulates Egr-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2-Elk-1 and NF-kappaB.

Authors:  Rukhsana N Hasan; Andrew I Schafer
Journal:  Circ Res       Date:  2007-10-25       Impact factor: 17.367

9.  Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.

Authors:  Florian Bea; Erwin Blessing; Monica I Shelley; Jennifer M Shultz; Michael E Rosenfeld
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

Review 10.  Inflammation at the molecular interface of atherogenesis: an anthropological journey.

Authors:  Brian D Lamon; David P Hajjar
Journal:  Am J Pathol       Date:  2008-11       Impact factor: 4.307

View more
  2 in total

Review 1.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.

Authors:  Anna Severino; Chiara Zara; Mara Campioni; Davide Flego; Giulia Angelini; Daniela Pedicino; Ada Francesca Giglio; Francesco Trotta; Simona Giubilato; Vincenzo Pazzano; Claudia Lucci; Antonio Iaconelli; Aureliano Ruggio; Luigi Marzio Biasucci; Filippo Crea; Giovanna Liuzzo
Journal:  Oncotarget       Date:  2017-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.